MedTrace Logo

The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta

NCT01279369 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2018-05-07

No results posted yet for this study

Summary

The purpose of this study is to determine if the presence of fetal fibronectin in the cervicovaginal secretions of pregnant patients with minor maternal trauma predicts impending preterm delivery due to abruptio placenta.

Conditions

  • Pregnancy Related
  • Trauma
  • Abruptio Placentae

Sponsors & Collaborators

  • Winthrop University Hospital

    lead OTHER

Principal Investigators

  • Wendy L. Kinzler, M.D. · Winthrop University Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01279369 on ClinicalTrials.gov